Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05156398 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety Study of Rimegepant for the Preventative Treatment of Migraine in Pediatric Subjects
A Phase 3 study of Migraine, sponsored by Pfizer.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 640
- Enrollment target
- 20
- Study locations
NCT05156398 is a Phase 3 study of Migraine that is actively recruiting participants, run by Pfizer. The registered enrollment target is 640 participants, above the 352-participant average among 102 other Migraine trials with a reported enrollment target (82% higher). The trial reports 20 study locations across 9 states.
The verdict
NCT05156398, a Phase 3 study of Migraine, is actively recruiting participants, sponsored by Pfizer.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 640 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to compare the efficacy and safety of rimegepant to placebo as a preventative treatment for migraine in children and adolescents ≥ 6 to \<18 years with episodic migraine.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Rimegepant
Study Locations (20)
Florida
- Accel Research Sites Network - Edgewater Clinical Research Unit - Edgewater
- Direct Helpers Research Center - Hialeah
- New Med Research, Inc - Hollywood
- Complete Health Research - Ormond Beach
- D&H Tamarac Research Center LLC - Tamarac
- Santos Research Center, CORP - Tampa
Georgia
- Augusta University - Augusta
- WR-Mount Vernon Clinical Research, LLC - Sandy Springs
- Meridian Clinical Research, LLC - Savannah
- Extraordinary Family Healthcare - Snellville
- Renew Health Clinical Research LLC - Snellville
California
- Advanced Investigative Medicine, Inc. - Hawthorne
- Velocity Clinical Research San Diego - La Mesa
Colorado
- Colorado Springs Neurological Associates - Colorado Springs
- Advanced Neurosciences Research, LLC - Fort Collins
Arkansas
- The Belinga Clinic - Fort Smith
District of Columbia
- Meridian Clinical Research, LLC - Washington D.C.
Idaho
- Northwest Clinical Trials, Inc. - Boise
Illinois
- Diamond Headache Clinic - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 640 participants |
| Start Date | 2022-02-28 |
| Est. Completion | 2032-11-27 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05156398
The ClinicalTrials.gov registry entry for NCT05156398 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 640 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 352-participant average among 102 other Migraine trials with a reported enrollment target (82% higher). The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Migraine appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT05156398 reports 20 study locations spanning 9 distinct geographic areas - top geographies include Florida, Georgia, California.
Frequently Asked Questions
What is clinical trial NCT05156398 about?
NCT05156398 is a clinical study titled "Efficacy and Safety Study of Rimegepant for the Preventative Treatment of Migraine in Pediatric Subjects". The purpose of this study is to compare the efficacy and safety of rimegepant to placebo as a preventative treatment for migraine in children and adolescents ≥ 6 to \<18 years with episodic migraine.
What is the current status of trial NCT05156398?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 640 participants. The study started on 2022-02-28. Estimated completion is 2032-11-27.
What conditions does trial NCT05156398 study?
This clinical trial studies the following conditions: Migraine.
What interventions are being tested in trial NCT05156398?
The interventions under investigation include: Placebo (DRUG), Rimegepant (DRUG).
Who is sponsoring clinical trial NCT05156398?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05156398 being conducted?
This trial has 20 study locations across Arkansas, California, Colorado, District of Columbia, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Migraine
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine
RECRUITING · Phase 3
-
A Study to Learn About the Study Medicine Called Rimegepant in Adolescents With Frequent Migraine
RECRUITING · Phase 3
-
Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17)
RECRUITING · Phase 3
-
A Study With Eptinezumab in Children and Adolescents (6 to 17 Years) With Chronic or Episodic Migraine
RECRUITING · Phase 3
-
Effectiveness of Magnesium in Addition to Prochlorperazine for the Treatment of Migraines
RECRUITING · Phase 3
-
Efficacy and Safety of Erenumab in Pediatric Participants With Episodic Migraine
ACTIVE NOT RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.